Notifications
Back

Pipeline


Pipeline

PharmAbcine has focused on the development of novel antibody therapeutics since the company’s foundation in 2008 and laid the groundwork for the commercialization of olinvacimab, PMC-309, PMC-403, and PMC-402.


We will also become an innovative global biotech company through the development of other new candidates such as PMC-005BL, PMC-122, PMC-401, and PMC-401s

Core Pipeline

 

 Olinvacimab (TTAC-0001)


   Angiogenesis Inhibitor

   VEGFR2

   Clinical

   mAb


  

  PMC-309


   Immune checkpoint inhibitor

   VISTA

   Preclinical

   mAb


  

  PMC-402


   Immune Activator

   TIE2

   Preclinical 

   mAb


  

  PMC-403


   Vessel-normalizer

   TIE2

   Preclinical 

   mAb





     2F, Research Building 2, 70,

     Yuseong-daero 1689 beon-gil,
     Yuseong-gu, Daejeon, 34047, Republic of Korea


     HQ +82-42-863-2017 

     R&D Center +82-42-861-2017

     Investor Relations +70-4294-6097 

     FAX +82-42-863-2080 


     COPYRIGHT BY PharmAbcine Inc.

     ALL RIGHTS RESERVE